Enhertu
AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC
October 23, 2023Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology
AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …
AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial
September 11, 2023Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial
AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …
Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC
August 23, 2023Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan
Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
August 14, 2026
